Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03709121
Other study ID # ADX-102-AC-011
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 2, 2018
Est. completion date March 20, 2019

Study information

Verified date October 2018
Source Aldeyra Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Reproxalap Ophthalmic Solution (0.25%)
Reproxalap Ophthalmic Solution (0.25%) dosed twice.
Reproxalap Ophthalmic Solution (0.5%)
Reproxalap Ophthalmic Solution (0.5%) dosed twice.
Vehicle Ophthalmic Solution
Vehicle Ophthalmic Solution dosed twice.

Locations

Country Name City State
Canada Inflamax Research Limited Mississauga Ontario

Sponsors (1)

Lead Sponsor Collaborator
Aldeyra Therapeutics, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ocular itching evaluated by the Subject. The method of assessment for this exploratory outcome includes the visual analog scale (VAS). Efficacy assessment period (Week 1 through Week 6).
Secondary Safety assessment. Safety assessment as determined by collection of Adverse Events Safety assessment period (Week 1 through week 6)
See also
  Status Clinical Trial Phase
Completed NCT00501527 - Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense Phase 2
Completed NCT00422149 - Twin SUBLIVAC® Grasses Clinical Efficacy Study Phase 3
Completed NCT01470118 - A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Phase 4
Completed NCT02555761 - Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Completed NCT01732757 - A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Phase 4
Recruiting NCT04299399 - Corneal Biomechanical Changes of Allergic Conjunctivitis
Completed NCT00917488 - Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP). Phase 2
Completed NCT03375775 - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children N/A
Completed NCT02082262 - AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis Phase 3
Withdrawn NCT01541904 - Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis Phase 2
Completed NCT00311844 - A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Phase 4
Completed NCT02161146 - AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Phase 3
Completed NCT00718744 - Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units Phase 2
Recruiting NCT03186755 - Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Phase 4
Completed NCT01987765 - Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea N/A
Completed NCT06063044 - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed NCT01289431 - Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis Phase 2
Completed NCT00655109 - A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Phase 4
Completed NCT00424398 - Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis Phase 2/Phase 3
Completed NCT03012165 - A Study of ADX-102 in Subjects With Allergic Conjunctivitis Phase 2